Brokerages expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to report sales of $3.08 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.27 million and the lowest estimate coming in at $2.50 million. The firm is scheduled to report its next quarterly earnings report on Monday, March 9th.
On average, analysts expect that Kala Pharmaceuticals will report full-year sales of $7.99 million for the current year, with estimates ranging from $7.40 million to $9.17 million. For the next fiscal year, analysts forecast that the business will post sales of $29.61 million, with estimates ranging from $17.16 million to $46.39 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.
A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target (down from $12.00) on shares of Kala Pharmaceuticals in a report on Monday, November 11th. Zacks Investment Research lowered shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 19th. Oppenheimer set a $9.00 price target on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Wedbush restated an “outperform” rating and issued a $51.00 price objective on shares of Kala Pharmaceuticals in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $17.85.
Shares of Kala Pharmaceuticals stock traded down $0.12 during trading hours on Friday, hitting $4.02. The company’s stock had a trading volume of 5,195 shares, compared to its average volume of 237,514. Kala Pharmaceuticals has a twelve month low of $3.24 and a twelve month high of $9.25. The firm has a fifty day moving average of $3.81 and a 200-day moving average of $4.74. The stock has a market cap of $144.72 million, a price-to-earnings ratio of -1.64 and a beta of 2.21. The company has a debt-to-equity ratio of 1.65, a quick ratio of 5.94 and a current ratio of 6.25.
A number of institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can lifted its stake in Kala Pharmaceuticals by 148.5% in the second quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock worth $26,000 after acquiring an additional 2,399 shares during the last quarter. Greenwich Wealth Management LLC grew its stake in Kala Pharmaceuticals by 28.7% during the 2nd quarter. Greenwich Wealth Management LLC now owns 13,000 shares of the company’s stock worth $83,000 after buying an additional 2,900 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after buying an additional 5,806 shares during the period. Marshall Wace LLP purchased a new stake in Kala Pharmaceuticals in the first quarter valued at approximately $325,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Kala Pharmaceuticals by 34.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 51,405 shares of the company’s stock valued at $328,000 after buying an additional 13,271 shares during the last quarter. Institutional investors own 64.21% of the company’s stock.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Story: What is a balanced fund?
Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.